Vyne Therapeutics INC 10-Q quarterly reports

Yarrow Bioscience, Inc. (formerly VYNE Therapeutics) reported its Q2 2026 results, highlighting the completion of its merger with Yarrow and a continued focus on its lead candidate YB-101, while managing significant accumulated deficits and future funding needs.

VYNE Therapeutics reported a reduced net loss for Q3 2025, but terminated its Phase 2b repibresib trial for vitiligo and faces a partial clinical hold on VYN202, prompting a strategic review and cost reductions.

VYNE Therapeutics reported mixed clinical trial results for VYN202 and repibresib, leading to trial terminations, while implementing cost reductions to extend its cash runway into the first half of 2027.

VYNE Therapeutics announces its Q1 2025 financial results, including a net loss of $8.6 million, and reports a clinical hold on its Phase 1b trial of VYN202 due to testicular toxicity observed in preclinical studies.

VYNE Therapeutics reported a net loss of $12.16 million for the third quarter of 2024, with increased research and development expenses due to ongoing clinical trials.

VYNE Therapeutics reported a net loss of $15.7 million for the first half of 2024, while advancing its clinical programs for VYN201 and VYN202.

VYNE Therapeutics reported a net loss of $6.2 million for the first quarter of 2024, while advancing its clinical programs for immuno-inflammatory conditions.